Sanofi India Q3 Results Live: Profit Falls by 45.89% YOY
Sanofi India Q3 Results Live: Revenue decreased by 26.67% YoY & profit decreased by 45.89% YoY.
Sanofi India Q3 Results Live : Sanofi India announced its Q3 results on November 7, 2024, revealing a significant decline in both revenue and profit. The company reported a topline decrease of 26.67% year-over-year, alongside a staggering profit drop of 45.89% compared to the same quarter last year.
In comparison to the previous quarter, Sanofi India saw a revenue growth of 13.05%, while profit decreased by 20.35%. This indicates a mixed performance, with some recovery on a sequential basis despite the year-over-year declines.
The company's selling, general, and administrative expenses have shown a positive trend, declining by 5.81% quarter-over-quarter and by 39.16% year-over-year. This reduction in expenses may provide some relief amid falling revenues.
Operating income for Q3 was reported to be up by 3.75% quarter-over-quarter, though it still reflected a significant year-over-year decrease of 44.18%. This suggests challenges in maintaining profitability despite cost-cutting measures.
Earnings per share (EPS) also took a hit, standing at ₹35.69 for Q3, marking a decrease of 45.88% year-over-year. This decline is likely to concern investors as it reflects the overall profitability challenges faced by the company.
In terms of stock performance, Sanofi India has experienced a -3.48% return over the past week. However, the company has delivered a 29.46% return over the last six months and a 29.96% return year-to-date, indicating resilience in the longer term despite recent volatility.
As of November 8, 2024, Sanofi India holds a market capitalization of ₹15,103.14 crore, with a 52-week trading range between ₹4,694.05 and ₹7,600. This range reflects the market's fluctuating sentiment regarding the company's performance.
Analyst sentiment appears cautiously optimistic, with 2 out of 3 analysts recommending a Buy rating and 1 analyst giving a Strong Buy rating. The consensus recommendation as of November 8, 2024, is to Strong Buy, indicating potential for recovery.
Sanofi India Financials
| Period | Q3 | Q2 | Q-o-Q Growth | Q3 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 524 | 463.5 | +13.05% | 714.6 | -26.67% |
| Selling/ General/ Admin Expenses Total | 56.7 | 60.2 | -5.81% | 93.2 | -39.16% |
| Depreciation/ Amortization | 9 | 9 | -0% | 9.9 | -9.09% |
| Total Operating Expense | 413.3 | 356.8 | +15.84% | 516.3 | -19.95% |
| Operating Income | 110.7 | 106.7 | +3.75% | 198.3 | -44.18% |
| Net Income Before Taxes | 112.6 | 92.1 | +22.26% | 209.8 | -46.33% |
| Net Income | 82.2 | 103.2 | -20.35% | 151.9 | -45.89% |
| Diluted Normalized EPS | 35.69 | 35.72 | -0.09% | 65.95 | -45.88% |
Stay updated on quarterly results with our results calendar
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess
FAQs
₹82.2Cr
₹524Cr
First Published:8 Nov 2024, 12:15 PM IST
- Top Gainers
- Top Losers
- 52 Week High